1. <source id="ymayf"></source>




          产生的小分子多肽,和MHC I结合形成MHC I-抗原肽复合物后,

          ?表达在癌细胞的表面。该复合物能够被CD8 T细胞识别,因此可以







          l? 自主知识产权,已授权。(**号:201310439062.2);

          l? 该方法得到的抗原肽是直接经细胞处理加工的抗原肽,真实有效;

          l? 抗原肽确定后可刺激CD8T细胞产生有肿瘤杀伤功能的CTL,可用


          l? 抗原肽所对应抗原可作为肿瘤标志物,用于肿瘤诊断试剂的研发


          l? 肿瘤新抗原疫苗的研发。

          Tumor antigen peptide identification platform

          ????Tumor antigen peptide is a new class of tumor markers. Tumor antigens

          ?are decomposed in the cell to generate peptides, which bind to MHC-1 to

          ?form MHC-1/antigen peptide complexes, and are displayed on cancer cell?

          surface. The complexes can be recognized by corresponding CD8 T cells,

          ?and therefore can be used as targets for diagnosis and treatment. Identification?

          of cancer cell tumor antigen peptides is, therefore, of great importance. We

          ?have developed a technical platform that integrates immune-biochemical /

          ?biophysical-bioinformatics methods to identify tumor antigen peptides. Our?

          studies on cultured cells have shown that the identified antigenic peptides

          ?can induce a highly specific tumor killing effect.


          Technical features and highlights

          1.????Patented technology involved (patent no. 201310439062.2);

          2.????The peptides thus obtained are those naturally processed by tumor?

          celss,?therefore?authantic and?useful;

          3.????The peptide(s) can be used to stimulate tumor specifc CD8 T cell?for


          4.????The peptide(s) origing protein(s) can be the tumor marker(s),? of potential

          ?use in diagnoisis;

          5.????Useful in anti-tumor peptide vaccine development.

          您是第 80123 位访客!